<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35590371</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1477-7819</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>20</Day>
            </PubDate>
          </JournalIssue>
          <Title>World journal of surgical oncology</Title>
          <ISOAbbreviation>World J Surg Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors.</ArticleTitle>
        <Pagination>
          <StartPage>159</StartPage>
          <MedlinePgn>159</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">159</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12957-022-02634-x</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Not all lung adenocarcinoma (LUAD) patients with activating epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs) as intended. Thus, biomarkers are needed to identify patients who benefit most from EGFR-targeted therapy. Our previous in vitro data has shown that the co-signal molecule B7-H3 determines EGFR-TKI gefitinib susceptibility of EGFR-mutated LUAD cell lines, based on the potential crosslinking between B7-H3-induced signaling and EGFR signaling.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We detected tumoral B7-H3 expression in the original biopsy from 56 treatment-naïve LUAD patients and analyzed the association between high/low B7-H3 expression with the clinical outcomes of first-line anti-EGFR therapy. The main criteria for the analysis of response were overall response rate (ORR), disease control rate (DCR), and progression-free survival (PFS), and the secondary criterion was overall survival (OS).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">In the subgroups of B7-H3 high and low expression, the ORR were 16.0% (4/25) and 74.2% (23/31) (p&lt;0.001), and the DCR were 36.0% (9/25) and 87.1% (27/31) (p&lt;0.001), respectively. The PFS of B7-H3 high [median 8.7, 95% confidence interval (CI) 4.0-13.4] was significantly worse than that of B7-H3 low (median not reached) [HR 6.54 (95% CI 2.18-19.60), p=0.001]. The median OS was 15.9 (95% CI 10.0-21.8) months in the B7-H3 high cohort and 25.7 (95% CI 9.0-42.4) months in the B7-H3 low subjects [HR 2.08 (95% CI 1.07-4.02), p=0.03], respectively. Both the univariate and multivariate analyses identified B7-H3 as an independent factor associated with poor PFS (p=0.001, p=0.000) and OS (p=0.03, p=0.015).</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">B7-H3 may serve as a potential biomarker to predict clinical outcomes in EGFR-mutated LUAD patients treated with first-line EGFR-TKIs.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Ying</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, Second Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Jun-Feng</ForeName>
            <Initials>JF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, Second Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hu</LastName>
            <ForeName>Bing-Qi</ForeName>
            <Initials>BQ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, Second Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, Second Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xian</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Second Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Feng</LastName>
            <ForeName>Zhen-Zhong</ForeName>
            <Initials>ZZ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Second Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yu-Ting</ForeName>
            <Initials>YT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Fa-Ming</ForeName>
            <Initials>FM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Huai-Dong</ForeName>
            <Initials>HD</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, Second Hospital of Anhui Medical University, Hefei, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Li-Wen</ForeName>
            <Initials>LW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Laboratory Medicine, Second Hospital of Anhui Medical University, Hefei, China. chenliwen@ahmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>World J Surg Oncol</MedlineTA>
        <NlmUniqueID>101170544</NlmUniqueID>
        <ISSNLinking>1477-7819</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C512478">EGFR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077192" MajorTopicYN="Y">Adenocarcinoma of Lung</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002289" MajorTopicYN="Y">Carcinoma, Non-Small-Cell Lung</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008175" MajorTopicYN="Y">Lung Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014157" MajorTopicYN="N">Transcription Factors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Biomarkers</Keyword>
        <Keyword MajorTopicYN="N">EGFR mutation</Keyword>
        <Keyword MajorTopicYN="N">Prognosis</Keyword>
        <Keyword MajorTopicYN="N">Survival</Keyword>
        <Keyword MajorTopicYN="N">Target therapy</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>23</Hour>
          <Minute>50</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35590371</ArticleId>
        <ArticleId IdType="pmc">PMC9121599</ArticleId>
        <ArticleId IdType="doi">10.1186/s12957-022-02634-x</ArticleId>
        <ArticleId IdType="pii">10.1186/s12957-022-02634-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Wu YL, Zhong WZ, Li LY, Zhang XT, Zhang L, Zhou CC, et al.  Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer. A meta-analysis based on updated individual patient data from six medical centers in mainland China. J Thorac Oncol. 2007;2:430–439. doi: 10.1097/01.JTO.0000268677.87496.4c.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.JTO.0000268677.87496.4c</ArticleId>
            <ArticleId IdType="pubmed">17473659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, et al.  Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res. 2005;11:2106–2110. doi: 10.1158/1078-0432.CCR-04-1853.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-04-1853</ArticleId>
            <ArticleId IdType="pubmed">15788655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barlesi F, Mazieres J, Merlio J-P, Debieuvre D, Mosser J, Lena H, et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) Lancet. 2016;387:1415–1426. doi: 10.1016/S0140-6736(16)00004-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)00004-0</ArticleId>
            <ArticleId IdType="pubmed">26777916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006. doi: 10.1001/jama.2014.3741.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2014.3741</ArticleId>
            <ArticleId IdType="pmc">PMC4163053</ArticleId>
            <ArticleId IdType="pubmed">24846037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. doi: 10.1016/S1470-2045(13)70604-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(13)70604-1</ArticleId>
            <ArticleId IdType="pubmed">24439929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S, Li X. Analysis of EGFR, KRAS, and PIK3CA gene mutation rates and clinical distribution in patients with different types of lung cancer. World J Surg Oncol. 2021;19(1):197. doi: 10.1186/s12957-021-02315-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-021-02315-1</ArticleId>
            <ArticleId IdType="pmc">PMC8254946</ArticleId>
            <ArticleId IdType="pubmed">34217313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Zhou X, Yao H, Li L. Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma. J Drug Target. 2020;28(9):861–872. doi: 10.1080/1061186X.2020.1737934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1061186X.2020.1737934</ArticleId>
            <ArticleId IdType="pubmed">32118494</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al.  Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–967. doi: 10.1056/NEJMoa0904554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0904554</ArticleId>
            <ArticleId IdType="pubmed">19692684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi: 10.1056/NEJMoa0909530.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0909530</ArticleId>
            <ArticleId IdType="pubmed">20573926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S, et al.  Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer. 2017;103:44–51. doi: 10.1016/j.lungcan.2016.11.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.lungcan.2016.11.013</ArticleId>
            <ArticleId IdType="pubmed">28024695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Altan M, Pelekanou V, Schalper KA, Toki M, Gaule P, Syrigos K, et al.  B7-H3 expression in NSCLC and its association with B7-H4, PD-L1 and tumor-infiltrating lymphocytes. Clin Cancer Res. 2017;23(17):5202–5209. doi: 10.1158/1078-0432.CCR-16-3107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-3107</ArticleId>
            <ArticleId IdType="pmc">PMC5581684</ArticleId>
            <ArticleId IdType="pubmed">28539467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yim J, Koh J, Kim S, Song SG, Ahn HK, Kim YA, et al.  Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer. Eur J Cancer. 2020;133:74–85. doi: 10.1016/j.ejca.2020.03.033.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2020.03.033</ArticleId>
            <ArticleId IdType="pubmed">32447027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu TT, Zhang T, Lu X, Wang RZ. B7-H3 promotes metastasis, proliferation, and epithelial-mesenchymal transition in lung adenocarcinoma. Onco Targets Ther. 2018;11:4693–4700. doi: 10.2147/OTT.S169811.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S169811</ArticleId>
            <ArticleId IdType="pmc">PMC6091475</ArticleId>
            <ArticleId IdType="pubmed">30127617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonk S, Tasdelen P, Kluth M, Hube-Magg C, Makrypidi-Fraune G, Möller K, et al.  High B7-H3 expression is linked to increased risk of prostate cancer progression. Pathol Int. 2020;70(10):733–742. doi: 10.1111/pin.12999.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/pin.12999</ArticleId>
            <ArticleId IdType="pubmed">32776718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE. Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells. Pigment Cell Melanoma Res. 2017;30(5):467–476. doi: 10.1111/pcmr.12599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/pcmr.12599</ArticleId>
            <ArticleId IdType="pubmed">28513992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin L, Cao L, Liu Y, Wang K, Zhang X, Qin X, et al.  B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3. Leukemia. 2019;33(6):1475–1486. doi: 10.1038/s41375-018-0331-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41375-018-0331-6</ArticleId>
            <ArticleId IdType="pubmed">30573782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong C, Tao B, Chen Y, Guo Z, Yang X, Peng L, et al.  B7-H3 regulates glioma growth and cell invasion through a JAK2/STAT3/Slug-dependent signaling pathway. Onco Targets Ther. 2020;13:2215–2224. doi: 10.2147/OTT.S237841.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S237841</ArticleId>
            <ArticleId IdType="pmc">PMC7075435</ArticleId>
            <ArticleId IdType="pubmed">32210587</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, Sun DX. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. 2015;21(1):570. doi: 10.1186/s12935-021-02216-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-021-02216-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L, Zhao Y. B7-H3 induces ovarian cancer drugs resistance through an PI3K/AKT/BCL-2 signaling pathway. Cancer Manag Res. 2019;11:10205–10214. doi: 10.2147/CMAR.S222224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S222224</ArticleId>
            <ArticleId IdType="pmc">PMC6899073</ArticleId>
            <ArticleId IdType="pubmed">31819652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, Liu J, Que L, Tang X. The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway. J Cancer. 2019;10(23):5770–5784. doi: 10.7150/jca.29838.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7150/jca.29838</ArticleId>
            <ArticleId IdType="pmc">PMC6843865</ArticleId>
            <ArticleId IdType="pubmed">31737114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding M, Liao H, Zhou N, Yang Y, Guan S, Chen L. B7-H3-induced signaling in lung adenocarcinoma cell lines with divergent epidermal growth factor receptor mutation patterns. Biomed Res Int. 2020;2020:8824805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7775133</ArticleId>
            <ArticleId IdType="pubmed">33426073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2008.10.026</ArticleId>
            <ArticleId IdType="pubmed">19097774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Villaruz LC, Socinski MA. The clinical viewpoint: definitions, limitations of RECIST, practical considerations of measurement. Clin Cancer Res. 2013;19(10):2629–2636. doi: 10.1158/1078-0432.CCR-12-2935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-12-2935</ArticleId>
            <ArticleId IdType="pmc">PMC4844002</ArticleId>
            <ArticleId IdType="pubmed">23669423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, et al.  Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma. Ann Diagn Pathol. 2020;46:151483. doi: 10.1016/j.anndiagpath.2020.151483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.anndiagpath.2020.151483</ArticleId>
            <ArticleId IdType="pubmed">32143173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu QX, Li EM, Zhang YF, Liao LD, Xu XE, Wu ZY, et al.  Overexpression of sigma1 receptor and its positive associations with pathologic TNM classification in esophageal squamous cell carcinoma. J Histochem Cytochem. 2012;60(6):457–466. doi: 10.1369/0022155412443542.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1369/0022155412443542</ArticleId>
            <ArticleId IdType="pmc">PMC3393071</ArticleId>
            <ArticleId IdType="pubmed">22511599</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Meng F, Wang J, Liu M, Yang G, Song R, et al.  A novel oxoglutarate dehydrogenase-like mediated miR-214/TWIST1 negative feedback loop inhibits pancreatic cancer growth and metastasis. Clin Cancer Res. 2019;25(17):5407–5421.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31175094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu X, Li R, Zhu P, Zhang P, Chen J, Lin Y, Chen Y. Clinical efficacy and safety of maintenance therapy for advanced non-small cell lung cancer: a retrospective real-world study. World J Surg Oncol. 2021;19(1):231. doi: 10.1186/s12957-021-02340-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-021-02340-0</ArticleId>
            <ArticleId IdType="pmc">PMC8349029</ArticleId>
            <ArticleId IdType="pubmed">34362384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng Z, Lin H, Zhou K, Deng S, Mei J. Predictive value of pretreatment PD-L1 expression in EGFR-mutant non-small cell lung cancer: a meta-analysis. World J Surg Oncol. 2021;19(1):145. doi: 10.1186/s12957-021-02254-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-021-02254-x</ArticleId>
            <ArticleId IdType="pmc">PMC8106834</ArticleId>
            <ArticleId IdType="pubmed">33964931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol. 2010;7(7):401–414. doi: 10.1038/nrclinonc.2010.64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2010.64</ArticleId>
            <ArticleId IdType="pubmed">20551945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al.  First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128. doi: 10.1200/JCO.2011.36.8456.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2011.36.8456</ArticleId>
            <ArticleId IdType="pubmed">22370314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239–246. doi: 10.1016/S1470-2045(11)70393-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(11)70393-X</ArticleId>
            <ArticleId IdType="pubmed">22285168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128. doi: 10.1016/S1470-2045(09)70364-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(09)70364-X</ArticleId>
            <ArticleId IdType="pubmed">20022809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. doi: 10.1056/NEJMoa0810699.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0810699</ArticleId>
            <ArticleId IdType="pubmed">19692680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi: 10.1016/S1470-2045(11)70184-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(11)70184-X</ArticleId>
            <ArticleId IdType="pubmed">21783417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manja V, Lakshminrusimha S. Epidemiology and Clinical Research Design, Part 1: Study Types. Neoreviews. 2014;15(12):e558–e569. doi: 10.1542/neo.15-12-e558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/neo.15-12-e558</ArticleId>
            <ArticleId IdType="pmc">PMC4384651</ArticleId>
            <ArticleId IdType="pubmed">25848346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia E, Ren N, Guo B, Cui Z, Zhang B, Xue J. Construction and validation of a novel prognostic model for lung squamous cell cancer based on N6-methyladenosine-related genes. World J Surg Oncol. 2022;20(1):59. doi: 10.1186/s12957-022-02509-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-022-02509-1</ArticleId>
            <ArticleId IdType="pmc">PMC8883700</ArticleId>
            <ArticleId IdType="pubmed">35220962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Gao Y, Li X, Zhang J, Liu T, Feng X, et al.  Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study. World J Surg Oncol. 2017;15(1):197. doi: 10.1186/s12957-017-1251-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-017-1251-z</ArticleId>
            <ArticleId IdType="pmc">PMC5674232</ArticleId>
            <ArticleId IdType="pubmed">29110716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chai Y, Ma Y, Feng W, Lu H, Jin L. Effect of surgery on survival in patients with stage III N2 small cell lung cancer: propensity score matching analysis and nomogram development and validation. World J Surg Oncol. 2021;19(1):258. doi: 10.1186/s12957-021-02364-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-021-02364-6</ArticleId>
            <ArticleId IdType="pmc">PMC8404296</ArticleId>
            <ArticleId IdType="pubmed">34461929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu LL, Lai JJ, Liu X, Huang YY, Lin P, Long H, et al.  Association between number of dissected lymph nodes and survival in stage IA non-small cell lung cancer: a propensity score matching analysis. World J Surg Oncol. 2020;18(1):322. doi: 10.1186/s12957-020-02090-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-020-02090-5</ArticleId>
            <ArticleId IdType="pmc">PMC7722454</ArticleId>
            <ArticleId IdType="pubmed">33287841</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
